Skip to main content
Erschienen in: Clinical Rheumatology 1/2021

15.06.2020 | Original Article

Interleukin-29 and interleukin-28A induce migration of neutrophils in rheumatoid arthritis

verfasst von: Ting-shuang Xu, Shu-yuan Jia, Ping Li

Erschienen in: Clinical Rheumatology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Type III Interferons, interleukin (IL)-29 and IL-28A, have been implicated in the inflammatory response of rheumatoid arthritis (RA). Increasing evidence suggests an important role of neutrophils in the pathogenesis of RA. However, the underlying mechanism remains unclear. Therefore, we investigated the expression of the receptor of these type III interferons, IL-28R1, on the neutrophils of RA patients, and further explored the roles of IL-29 and IL-28A on neutrophil activity.

Methods

Neutrophils were extracted from peripheral blood of patients who met the diagnostic criteria for RA and healthy controls. The serum levels of IL-29 and IL-28A in RA patients and healthy controls were examined by enzyme-linked immunoassay, and the expression of IL-28R1 on neutrophils was determined by flow cytometry. A transwell assay was performed to determine the chemotactic ability of IL-29 and IL-28A to neutrophils in RA patients.

Results

The serum IL-29 but not IL-28A levels were significantly elevated in RA patients, and neither was correlated with RA disease activity. IL-28R1 levels on neutrophils were significantly (p < 0.001) elevated in patients with RA (51.85% (36.10%, 67.03%)) compared with those of healthy controls (4.13% (3.54%, 7.96%)), and IL-29 and IL-28A had a significant chemotactic effect on neutrophils from the peripheral blood of RA patients.

Conclusion

IL-29 and IL-28A play an important role in regulating neutrophils which participate in the pathogenesis of RA. Therefore, inhibiting IL-29 and IL-28A may be a new therapeutic strategy for RA.
Key points
• The IL-28R1 levels were increased in neutrophils of RA patients, suggesting its potentially important role in the pathogenesis of RA.
• IL-29 and IL-28A induce the migration of neutrophils that participate in the development of RA.
Literatur
2.
Zurück zum Zitat Weinmann P, Moura RA, Caetano-Lopes JR, Pereira PA, Canhão H, Queiroz MV, Fonseca JE (2007) Delayed neutrophil apoptosis in very early rheumatoid arthritis patients is abrogated by methotrexate therapy. Clin Exp Rheumatol 25:885–887PubMed Weinmann P, Moura RA, Caetano-Lopes JR, Pereira PA, Canhão H, Queiroz MV, Fonseca JE (2007) Delayed neutrophil apoptosis in very early rheumatoid arthritis patients is abrogated by methotrexate therapy. Clin Exp Rheumatol 25:885–887PubMed
3.
Zurück zum Zitat Kotenko Sergei V, Grant G, Baurin Vitaliy V, Anita L-A, Shen M, Shah Nital K, Langer Jerome A, Faruk S, Harold D, Donnelly Raymond P (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69–77. https://doi.org/10.1038/ni875CrossRefPubMed Kotenko Sergei V, Grant G, Baurin Vitaliy V, Anita L-A, Shen M, Shah Nital K, Langer Jerome A, Faruk S, Harold D, Donnelly Raymond P (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69–77. https://​doi.​org/​10.​1038/​ni875CrossRefPubMed
6.
Zurück zum Zitat Daniel A, Tuhina N, Silman Alan J, Julia F, Felson David T et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581. https://doi.org/10.1002/art.27584CrossRef Daniel A, Tuhina N, Silman Alan J, Julia F, Felson David T et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581. https://​doi.​org/​10.​1002/​art.​27584CrossRef
9.
Zurück zum Zitat Witte K, Gruetz G, Volk H-D, Looman A-C, Asadullah K, Sterry W, Sabat R, Wolk K (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10:702–714. https://doi.org/10.1038/gene.2009.72CrossRefPubMed Witte K, Gruetz G, Volk H-D, Looman A-C, Asadullah K, Sterry W, Sabat R, Wolk K (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10:702–714. https://​doi.​org/​10.​1038/​gene.​2009.​72CrossRefPubMed
12.
Zurück zum Zitat You-Jung H, Seok CY, Ha KE et al (2018) Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren’s syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clin Exp Rheumatol 112(3):31–40 You-Jung H, Seok CY, Ha KE et al (2018) Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren’s syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clin Exp Rheumatol 112(3):31–40
13.
Zurück zum Zitat Katrina B, Eames Hayley L, Miriam W, Byrne Adam J, Dany P, Pease James E, Sean D, Fiona MC, Williams Richard O, Udalova Irina A (2015) IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exp Med 212:845–853. https://doi.org/10.1084/jem.20140995CrossRef Katrina B, Eames Hayley L, Miriam W, Byrne Adam J, Dany P, Pease James E, Sean D, Fiona MC, Williams Richard O, Udalova Irina A (2015) IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exp Med 212:845–853. https://​doi.​org/​10.​1084/​jem.​20140995CrossRef
18.
24.
Metadaten
Titel
Interleukin-29 and interleukin-28A induce migration of neutrophils in rheumatoid arthritis
verfasst von
Ting-shuang Xu
Shu-yuan Jia
Ping Li
Publikationsdatum
15.06.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 1/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05211-3

Weitere Artikel der Ausgabe 1/2021

Clinical Rheumatology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.